Biocon: Company Gets Health Canada Approval For Yesintak Ustekinumab Autoinjector Pen To Treat Autoimmune Diseases.

 29 Jul 2026 08:34 AM

Biocon: Company Gets Health Canada Approval For Yesintak Ustekinumab Autoinjector Pen To Treat Autoimmune Diseases.

Biocon: Biocon Malaysia Gets EMA Approval For New Insulin Drug Production Unit

 16 Jul 2026 08:51 AM

Biocon: Biocon Malaysia Gets EMA Approval For New Insulin Drug Production Unit

Biocon: Bernstein on Biocon Maintains Underperform with Target Price of ₹326 as Viatris’ block deal exit does not change Biocon’s earnings outlook, citing high leverage, slow monetization of Biologics and Syngene investments, rising biosimilar competition due to policy changes, and succession concerns, with the $2 billion revenue milestone likely 4–5 years away.

 15 Jul 2026 09:01 AM

Biocon: Bernstein on Biocon Maintains Underperform with Target Price of ₹326 as Viatris’ block deal exit does not change Biocon’s earnings outlook, citing high leverage, slow monetization of Biologics and Syngene investments, rising biosimilar competition due to policy changes, and succession concerns, with the $2 billion revenue milestone likely 4–5 years away.

Biocon: DAM Capital on Biocon Maintains Buy with Target Price of ₹495 as Mylan’s exit removes a long-standing overhang, while the biosimilars business has turned the corner with H2FY27 growth expected from bUstekinumab, bAspart, bDenosumab and bAflibercept launches, supporting a 15% FY26–28 revenue CAGR and 26–27% EBITDA margins.

 15 Jul 2026 09:01 AM

Biocon: DAM Capital on Biocon Maintains Buy with Target Price of ₹495 as Mylan’s exit removes a long-standing overhang, while the biosimilars business has turned the corner with H2FY27 growth expected from bUstekinumab, bAspart, bDenosumab and bAflibercept launches, supporting a 15% FY26–28 revenue CAGR and 26–27% EBITDA margins.

BIOCON: RS 1819.34CR NSE BLOCK TRADE; FOR ~45483460 SHARES, AT RS 400 (PRE-OPEN)

 14 Jul 2026 09:12 AM

BIOCON: RS 1819.34CR NSE BLOCK TRADE; FOR ~45483460 SHARES, AT RS 400 (PRE-OPEN)

Biocon: Mylan Plans To Sell A Portion Of Its 5.64% Stake -CNBC TV18.

 09 Jul 2026 02:48 PM

Biocon: Mylan Plans To Sell A Portion Of Its 5.64% Stake -CNBC TV18.

Biocon: Viatris Owned Mylan Likely To Sell Part Of Its 5.64% Stake || Stake Sale Via Block Deals Is Expected Soon - CNBCTV18

 09 Jul 2026 02:49 PM

Biocon: Viatris Owned Mylan Likely To Sell Part Of Its 5.64% Stake || Stake Sale Via Block Deals Is Expected Soon - CNBCTV18

Biocon: Company Releases Phase III Trial Data Backing Yesafili Biosimilar Before U.S. Launch

 09 Jul 2026 08:52 AM

Biocon: Company Releases Phase III Trial Data Backing Yesafili Biosimilar Before U.S. Launch

Biocon: Company Strengthens Diabetes Care Efforts In Malaysia As Partner Duopharma Biotech Wins Insulin Tenders Exceeding MYR 225 Million, Providing Short-Acting Recombinant Human Insulin, Insulin Glargine, And Insulin Aspart.

 24 Jun 2026 09:00 AM

Biocon: Company Strengthens Diabetes Care Efforts In Malaysia As Partner Duopharma Biotech Wins Insulin Tenders Exceeding MYR 225 Million, Providing Short-Acting Recombinant Human Insulin, Insulin Glargine, And Insulin Aspart.

Biocon: Invests ₹5.48 Crore In Ampin Solar Power SPV To Enhance Green Energy Usage.

 10 Jun 2026 07:59 PM

Biocon: Invests ₹5.48 Crore In Ampin Solar Power SPV To Enhance Green Energy Usage.

Biocon: Company Aims to Use Entire Free Cash Flow for Reducing Debt, Anticipating Net Debt to Stay Between $1.1 Billion and $1.2 Billion. FY27-FY28 Outlook Shows Growth Expected in Later Year Due to Multiple New Product Launches.

 11 May 2026 08:31 AM

Biocon: Company Aims to Use Entire Free Cash Flow for Reducing Debt, Anticipating Net Debt to Stay Between $1.1 Billion and $1.2 Billion. FY27-FY28 Outlook Shows Growth Expected in Later Year Due to Multiple New Product Launches.

Biocon: Company Anticipates Growth For Biosimilar Aspart In Second Half Of FY27, Leveraging Full Market Share In Certain US Closed-Door Networks.

 11 May 2026 08:31 AM

Biocon: Company Anticipates Growth For Biosimilar Aspart In Second Half Of FY27, Leveraging Full Market Share In Certain US Closed-Door Networks.

Biocon: Company Aims to Boost Profitability in Generics as New Products Stabilize and Utilization Rises, Plus Focus on Execution for CRDMO Business Syngene.

 11 May 2026 08:31 AM

Biocon: Company Aims to Boost Profitability in Generics as New Products Stabilize and Utilization Rises, Plus Focus on Execution for CRDMO Business Syngene.

Biocon: Co Approved Acquiring ~2% Stake In Biocon Biologics From Employees/other Shareholders Via Issuance Of Up To 87.9 Lakh Shares At ₹376.16 Each (≈₹330.7 Crore) Through A Preferential Allotment, Subject To Approvals, To Consolidate Ownership In Its Subsidiary.

 08 May 2026 07:52 AM

Biocon: Co Approved Acquiring ~2% Stake In Biocon Biologics From Employees/other Shareholders Via Issuance Of Up To 87.9 Lakh Shares At ₹376.16 Each (≈₹330.7 Crore) Through A Preferential Allotment, Subject To Approvals, To Consolidate Ownership In Its Subsidiary.

BIOCON: Q4 CONS NET PROFIT 1.26B RUPEES VS 3.4B (YOY) || Q4 REVENUE 45.2B RUPEES VS 44.2B (YOY)

 08 May 2026 07:49 AM

BIOCON: Q4 CONS NET PROFIT 1.26B RUPEES VS 3.4B (YOY) || Q4 REVENUE 45.2B RUPEES VS 44.2B (YOY)

BIOCON: Q4 EBITDA 10.2B RUPEES VS 10.8B (YOY) || Q4 EBITDA MARGIN 22.59% VS 24.41% (YOY)

 08 May 2026 07:49 AM

BIOCON: Q4 EBITDA 10.2B RUPEES VS 10.8B (YOY) || Q4 EBITDA MARGIN 22.59% VS 24.41% (YOY)

Biocon: Kiran Mazumdar-Shaw Names Niece Claire Mazumdaar As Her Successor. - RTRS Citing Fortune India.

 05 May 2026 09:50 AM

Biocon: Kiran Mazumdar-Shaw Names Niece Claire Mazumdaar As Her Successor. - RTRS Citing Fortune India.

Biocon: Company Anticipates Margin Pressure for Insulin Glargine - NDTV

 05 May 2026 09:38 AM

Biocon: Company Anticipates Margin Pressure for Insulin Glargine - NDTV

Biocon: U.S. FDA Finishes Pre-License Review At Biocon's Bengaluru Biosimilars Plant; Notes 5 Procedural Observations But No Data Issues Found.

 30 Apr 2026 09:15 AM

Biocon: U.S. FDA Finishes Pre-License Review At Biocon's Bengaluru Biosimilars Plant; Notes 5 Procedural Observations But No Data Issues Found.

Biocon: Co. Receives Health Canada Approval For Biosimilars Bosaya And Vevzuo, Expected To Help Over 2 Million Adults With Osteoporosis And Hundreds With Bone Metastases

 21 Apr 2026 08:47 AM

Biocon: Co. Receives Health Canada Approval For Biosimilars Bosaya And Vevzuo, Expected To Help Over 2 Million Adults With Osteoporosis And Hundreds With Bone Metastases